April 22, 2020 11:12 AM EDT

EMA approves Boehringer's systemic sclerosis therapy; Novartis' Kymriah wins RMAT status for follicular lymphoma

ENDPOINTS

→ The European Commission has approved Boehringer Ingelheim‘s nintedanib for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults. The OK …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA approves Boehringer's systemic sclerosis therapy; Novartis' Kymriah wins RMAT status for follicular lymphoma

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

EMA ap­proves Boehringer's sys­temic scle­ro­sis ther­a­py; No­var­tis' Kym­ri­ah wins RMAT sta­tus for fol­lic­u­lar lym­phoma

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

EMA approves Boehringer's systemic sclerosis therapy; Novartis' Kymriah wins RMAT status for follicular lymphoma